(Q34601313)

3 August 2017

1 reference

title

Tipranavir: a new protease inhibitor for the pediatric population (English)

1 reference

3 August 2017

Joshua D Courter

1

1 reference

3 August 2017

Jennifer E Girotto

series ordinal

2

1 reference

3 August 2017

Juan C Salazar

series ordinal

3

1 reference

3 August 2017

publication date

1 December 2008

1 reference

Expert Review of Anti-infective Therapy

3 August 2017

published in

1 reference

3 August 2017

volume

6

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

797-803

1 reference

3 August 2017

cites work

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Virologic efficacy of boosted double versus boosted single protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Tipranavir: a novel nonpeptidic protease inhibitor of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

Antiretroviral Treatment in Pediatric HIV Infection in the United States From Clinical Trials to Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.6.797

21 January 2018

Identifiers

DOI

10.1586/14787210.6.6.797

1 reference

3 August 2017

1 reference